EUVIMEDEUVIMED entdecken
Kohortenstudie

Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study

Yongtai Cho, Dongwon Yoon, Farzin Khosrow-Khavar, Minkyo Song, Eun Ha Kang, Ju Hwan Kim, Ju-Young Shin iD

Journal of Internal Medicine · 2025

DOI: 10.1111/joim.20064 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Yongtai Cho und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Colitis, Ulcerative, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evolving evidence suggests that patients undergoing treatment with Janus kinase inhibitors (JAKi) may face an increased risk of cardiovascular events, malignancies, and serious infections.

Objectives

We assessed cardiovascular, malignancy, and serious infection risks associated with JAKi use compared to tumor necrosis factor inhibitor (TNFi) use, which served as the active comparator, in patients with rheumatoid arthritis (RA) or ulcerative colitis (UC).

Methods

This study emulated a target trial using South Korea's nationwide claims database (2013–2023). We constructed two separate cohorts comprising new users of JAKi or TNFi with either RA or UC and performed overlap weighting to control for confounders. Outcomes included three‐point‐major adverse cardiovascular events (3P‐MACE) (cardiovascular death, myocardial infarction, and stroke), malignancy, and serious infection. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI).

Results

The RA cohort included 14,972 patients, with 4759 initiating JAKi. The UC cohort included 2085 patients, with 347 initiating JAKi. In the overall RA cohort, the weighted HR was 0.92 (95% CI 0.59–1.42) for 3P‐MACE, 1.61 (1.08–2.41) for malignancy, and 1.08 (0.94–1.23) for serious infection. In the overall UC cohort, the weighted HR was 0.98 (0.11–8.42) and 0.45 (0.26–0.78) for malignancy and serious infection, respectively. No 3P‐MACE cases were observed in JAKi users.

Conclusions

JAKis were associated with an elevated risk of malignancy but no significant difference in the risk of 3P‐MACE and serious infection among all patients with RA. Further data are needed regarding the risk of malignancy and 3P‐MACE in patients with UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsColitis, UlcerativeCardiovascular DiseasesNeoplasmsInfectionsHumansFemaleMaleMiddle AgedAdultRepublic of KoreaCohort StudiesAgedRisk Factors

Stichwörter der Autor:innen

Janus kinase inhibitordrug safetyrheumatoid arthritistumor necrosis factor inhibitorulcerative colitis

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Maryland, USA.
  • Department of Biostatistics and Epidemiology, School of Public Health, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA.
  • Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Healthcare Policy and Aging Research, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.

ORCID-Profile: Ju-Young Shin

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Cho, Y., Yoon, D., Khosrow-Khavar, F., Song, M., Kang, E. H., Kim, J. H., & Shin, J. Y. (2025). Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study. Journal of Internal Medicine. https://doi.org/10.1111/joim.20064

Vancouver

Cho Y, Yoon D, Khosrow-Khavar F, Song M, Kang EH, Kim JH, et al. Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study. Journal of Internal Medicine. 2025. doi:10.1111/joim.20064

BibTeX
@article{Cho2025,
  author = {Cho, Yongtai and Yoon, Dongwon and Khosrow-Khavar, Farzin and Song, Minkyo and Kang, Eun Ha and Kim, Ju Hwan and Shin, Ju-Young},
  title = {Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study},
  journal = {Journal of Internal Medicine},
  year = {2025},
  doi = {10.1111/joim.20064}
}
Kostenlos starten →